ClinicalTrials.gov
public full text
Public Domain
Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children
The purpose of the multicenter, randomized, open-label, controlled phase II study is to determine whether pegylated recombinant human growth hormone is effective in the treatment of children with growth hormone deficiency.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)#1140568
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency#993981
- Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm#913106
- Pegcetacoplan Long Term Safety and Efficacy Extension Study#915103
- A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency#127770
Record · ID 1072284
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive